Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
University of Pittsburgh
Washington University School of Medicine
All India Institute of Medical Sciences
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Johnson & Johnson Enterprise Innovation Inc.
Janssen Research & Development, LLC
Sun Yat-sen University
University of Pittsburgh
Seagen Inc.
Coherus Oncology, Inc.
NRG Oncology
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
AstraZeneca
Eastern Cooperative Oncology Group
Sun Yat-sen University
Sun Yat-sen University
First Affiliated Hospital of Guangxi Medical University
VSPharmTech Co.,Ltd.
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sun Yat-sen University
Affiliated Hospital of Guangdong Medical University
Tianjin Medical University Cancer Institute and Hospital
M.D. Anderson Cancer Center
Universität des Saarlandes
University of Florida
Institut Claudius Regaud
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shandong Cancer Hospital and Institute
NYU Langone Health
Eye & ENT Hospital of Fudan University
Eye & ENT Hospital of Fudan University
MediLink Therapeutics (Suzhou) Co., Ltd.
Centre Leon Berard
Mayo Clinic
Cedars-Sinai Medical Center
Rakuten Medical, Inc.
National University Hospital, Singapore
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
University of Michigan Rogel Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's